Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nevirapine BSA vs Weight-based Dosing in Pediatric HIV
NCT00273975Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2002
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nevirapine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve over one dosing interval at Day 28, Maximum observed concentration at Day 28 and 2 more. Started Jan 2002; status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00273975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00273975.